Close

move up move left move right move bottom

XARELTO® CarePath Support Program

Comprehensive support program to help patients start and stay on therapy

XARELTO® CarePath offers comprehensive support and services focused on:

  • Access tools to help start patients on therapy by making treatment accessible and affordable to all eligible patients

  • Education tools to help keep patients informed about their disease and the importance of staying on treatment to help support their success

  • Adherence tools to help patients stay on therapy through useful tools and reminders

  •  

    Business Associate Agreement (BAA)

    Sign and submit this BAA to ensure compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and allow Janssen to provide high levels of service.

  •  

    Business Investigation Form (BIF)

    Submit a BIF for each patient for whom you would like to complete an assessment of eligibility and coverage for XARELTO®. You can also use this form to request assistance with the prior authorization process for XARELTO®.

  •  

    Provider Portal

    Use the provider portal with real-time 24-hour access to submit benefit investigation requests electronically and review the status of your XARELTO® CarePath patients online.

  • XARELTO® CarePath Savings Card

    Assistance for patients with commercial insurance

    • Eligible patients with an approved chronic indication for XARELTO® (15 mg or 20 mg)*

    • Per calendar year, subject to $3400 maximum annual program benefit. No monthly cap

    For eligibility requirements and restrictions, visit XARELTO® CarePath or call 1-888-XARELTO (1-888-927-3586). A XARELTO® CarePath Trial Offer may also be available.

    *Not valid for patients enrolled in Medicare Part D or Medicaid.

  •  
  • XARELTO® CarePath Trial Offer

    Assistance for patients with federally funded Medicare, Medicaid, TRICARE, or commercial insurance

    • Eligible patients with an approved chronic indication for XARELTO® (15 mg or 20 mg) will receive up to a free 30-day supply

    • Subject to 1 use or 12 months from program start date, whichever comes first

    For eligibility requirements and restrictions, call 1-888-XARELTO (1-888-927-3586).

  •  
  • Other Patient Assistance Resources

    Assistance for patients with no insurance

    Johnson & Johnson Patient Assistance Foundation, Inc. (JJPAF) is committed to providing access to uninsured individuals who lack the financial resources to pay for their medicines.

    If your patient needs XARELTO® and is uninsured and unable to pay for their medicine, and you would like to see if they might qualify for assistance, please have them:

    • contact a JJPAF program specialist at 1-800-652-6227, 9:00 AM-6:00 PM ET, or

    • visit the Foundation website

    If a patient does not have coverage for XARELTO®, a comprehensive list of additional programs is available at Janssen Prescription Assistance.

 

Indications

 

IMPORTANT SAFETY INFORMATION

 

Indication and Important saftey Information

 

INDICATIONS

  • Reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF). There are limited data on the relative effectiveness of XARELTO® (rivaroxaban) and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well controlled.
  • Treatment of deep vein thrombosis (DVT).
  • Treatment of pulmonary embolism (PE).
  • Reduction in the risk of recurrence of DVT and of PE following initial 6 months treatment for DVT and/or PE.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing knee replacement surgery.
  • Prophylaxis of DVT, which may lead to PE in patients undergoing hip replacement surgery.